Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126468 | 0.87 | LMNA (0.42) | KEAP1NFE2L2LMNANPSR1MAPT | |
| SCHEMBL6485462 | 0.87 | LMNA (0.42) | KEAP1NFE2L2LMNANPSR1MAPT | |
| SCHEMBL7120675 | 0.86 | LMNA (0.40) | KEAP1NFE2L2LMNANPSR1MAPT | |
| SCHEMBL7159688 | 0.86 | LMNA (0.40) | KEAP1NFE2L2LMNANPSR1MAPT | |
| SCHEMBL7128377 | 0.85 | LMNA (0.38) | KEAP1NFE2L2LMNANPSR1MAPT | |
| SCHEMBL6542743 | 0.78 | LMNA (0.37) | KEAP1NFE2L2LMNANPSR1MAPT | |
| SCHEMBL6355171 | 0.74 | SMN1; SMN2 (0.52) | LMNANPSR1MAPTALDH1A1MEN1 | |
| SCHEMBL6357275 | 0.74 | EPHX2 (0.48) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6542192 | 0.74 | LMNA (0.50) | LMNANPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL8700410 | 0.73 | ALDH1A1 (0.47) | LMNAMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | ABRAHAM DONALD J (US) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | KEAP1 1093/4885NFE2L2 569/4885LMNA 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.